



***Think Globally...
Report Locally!***

2024: Health Care Professional's Guide to Disease Reporting in Michigan

A summary of the Michigan
Communicable Disease Rules



Version 2024

Michigan's Communicable Disease Rules

Michigan's communicable disease rules are promulgated under the authority conferred on the Department of Health and Human Services by section 5111 of Act No. 368 of the Public Acts of 1978, as amended, being 333.5111 of the Michigan Compiled Laws. Violations of these laws will be reported to the state of Michigan and may constitute a misdemeanor under MCL 333.2261. For additional reporting requirements regarding HIV and AIDS please refer to MCL 333.5101 *et seq.* Health care professionals are advised to consult with their local health departments or legal counsel if they have questions about their responsibilities regarding these rules.

The Michigan Department of Health and Human Services maintains, reviews, and revises the list of reportable conditions located on pages 6 and 11 at least annually. Please refer to the Michigan Communicable Disease Information website at www.michigan.gov/cdinfo or contact the Communicable Disease Division at the number below for the most recent list.

The Privacy Rule in the Health Insurance Portability and Accountability Act of 1996 (HIPAA) allows for the disclosure of protected health information, without individual client or patient authorization, to public health authorities, who are legally authorized to receive such reports for the purpose of preventing or controlling disease. 45 C.F.R. § 164.512(b)

Michigan Department of Health and Human Services
www.michigan.gov/mdhhs

Bureau of Infectious Disease Prevention

333 South Grand Avenue, Box 30195
Lansing, MI 48909

Communicable Disease and Emerging Zoonotic Infectious Disease Divisions

Phone: 517-335-8165
Fax: 517-335-8263

Division of Immunizations

Phone: 517-335-8159
Fax: 517-335-9855

Bureau of Laboratories

3350 N. Martin Luther King Jr. Blvd.
Lansing, MI 48909
Phone: 517-335-8063
Fax: 517-335-9631

After hours **Emergency** calls only: 517-335-9030

Table of Contents

| | |
|----------------------------------------------------------------------------------|----|
| WHY REPORT COMMUNICABLE DISEASES?..... | 1 |
| LOCAL HEALTH DEPARTMENT SYSTEM AND SERVICES..... | 2 |
| MICHIGAN LABORATORY RESPONSE NETWORK..... | 2 |
| A. Authorization and Obligation to Report..... | 3 |
| 1. Physicians and laboratories..... | 3 |
| 2. Who else may report..... | 3 |
| 3. Schools, daycares, and camps..... | 3 |
| B. How, Where, and When to Report..... | 4 |
| 1. Michigan Disease Surveillance System (MDSS)..... | 4 |
| 2. Duplicate reporting..... | 4 |
| 3. HIV Reporting..... | 4 |
| C. Content of the Report..... | 5 |
| 1. Physician's report..... | 5 |
| 2. Unusual outbreak or occurrence..... | 5 |
| 3. Laboratory report..... | 5 |
| D. Physician and Authorized Health Care Professional Reporting Requirements..... | 6 |
| 1. List of reportable diseases by condition..... | 6 |
| 2. Animal bites/rabies reporting..... | 7 |
| 3. Influenza Reporting..... | 8 |
| 4. Pregnancy status reporting and STI testing..... | 8 |
| E. Expedited partner therapy..... | 9 |
| F. Immunization Requirements and Reporting..... | 9 |
| 1. Michigan vaccination requirements..... | 9 |
| 2. Michigan vaccine programs..... | 9 |
| 3. Reporting to the Michigan Care Improvement Registry (MCIR)..... | 10 |
| 4. School and childcare immunization requirements..... | 10 |
| G. Laboratory Reporting Requirements..... | 11 |
| 1. List of reportable diseases by pathogen..... | 11 |
| 2. Carbapenemase-producing Organisms (CPO)..... | 12 |
| 3. Mycobacterium tuberculosis complex reporting and culture submission..... | 13 |
| 4. Rabies examination and reporting..... | 13 |
| 5. Viral hepatitis reporting..... | 14 |
| 6. Submission of other designated conditions specimens..... | 15 |
| H. Investigative Authority of Public Health Departments..... | 15 |
| 1. Access to information..... | 15 |
| 2. Assistance and support..... | 16 |
| 3. Validation of reporting..... | 16 |
| 4. Information to be provided..... | 16 |
| 5. Authority to investigate..... | 16 |
| I. Confidentiality..... | 16 |
| J. Isolation and Other Preventative Measures..... | 17 |
| K. Exclusion from School..... | 17 |
| CONSULTATION SERVICE AND BIBLIOGRAPHY..... | 18 |
| IMPORTANT WEBSITES..... | 19 |
| DIRECTORY OF MICHIGAN LABORATORY RESPONSE NETWORK..... | 20 |
| DIRECTORY OF MICHIGAN LOCAL HEALTH DEPARTMENTS..... | 21 |

Why Report Communicable Diseases?

The public health system depends upon reports of diseases to monitor the health of the community and to provide the basis for preventive action. The prompt required reporting by physicians, laboratory scientists, infection preventionists, and other care providers of both diagnosed and suspected communicable diseases allows for timely action by local and state public health personnel. This teamwork makes possible important benefits, as listed below, for individual patients and the community.

1. **Identification of outbreaks and epidemics.** The unusual occurrence, outbreak, or epidemic of any disease or condition must be reported to the local health department. The local health department will investigate to identify the source and control the spread of the disease and will report those findings to the Michigan Department of Health and Human Services (MDHHS, also referred to as “the Department”). R. 325.174(1), (5). Disease-specific surveillance protocols can be found under the “Communicable Diseases (A-Z)” link at: www.michigan.gov/cdinfo.
2. **Enabling preventive treatment and/or education to be provided.** Close contacts or sexual partners need to be identified for prophylaxis, treatment, and/or education about how to prevent the spread of some infections. See *generally*, R. 325.175(1).
3. **Successful targeting of prevention programs, identification of care needs, and efficient use of scarce prevention resources.** Public and private health care funding is scarce. State and local public health authorities and health care providers make difficult choices about what prevention and treatment services will be provided. Communicable disease data help to maximize the impact of these dollars.
4. **Evaluation of the success of long-term control efforts.** Public health programs need a means of assessing the continued success of control efforts for some diseases.
5. **Facilitation of epidemiologic research to uncover a preventable cause.** For some diseases of unknown etiology, reporting is needed to allow studies of the occurrence of the disease to help find the cause or modifiable risk increasing factors.
6. **Assistance with national and international disease surveillance and preparedness efforts.** For diseases that are unusual in Michigan, or for those that have the potential to be used as bioterrorism agents, we are part of a national network that the federal government depends on to determine whether national or international investigations are needed.
7. **Compliance with Michigan’s public health laws.** All physicians and laboratories are required by law to report certain cases of communicable disease. Violations of these laws will be reported to the state of Michigan and may constitute a misdemeanor under MCL 333.2261.

**ACCURATE AND COMPLETE DISEASE REPORTING IS ESSENTIAL
TO THE COMMUNITY’S HEALTH**

Local Health Department System and Services

Michigan is served by a system of local public health departments that provide basic public health services, including communicable disease-related services, to all Michigan citizens and health care providers in all areas of the state. Communicable-disease reports should be directed to the local health department.

The primary role of MDHHS in communicable disease control is to provide expert consultation, reference level diagnostic laboratory services, childhood vaccines, and support as needed to Michigan's local health departments. Local health departments function as administratively autonomous units, separate from MDHHS. As such, they set their own priorities for how they allocate the resources available to them. Most local health departments provide a wide range of communicable-disease-related services. Some of the communicable-disease-prevention-services that are frequently offered include:

- Communicable disease consultation, including information on testing and specimen requirements, and outbreak investigation
- Provision of diagnostic, treatment, and partner services for sexually-transmitted infections
- Immunization clinics
- Animal bite consultation services
- Tuberculosis consultation and treatment services

The telephone number of your local health department is usually listed on their website and in the phone book with other county services (Note: Detroit is the only city in Michigan that has a city health department). It may be helpful to write your local health department phone number on the cover of this booklet.

For a directory of Michigan local public health departments see page 21 of this guide.

Michigan Laboratory Response Network

The MDHHS Bureau of Laboratories (BOL) is equipped to respond to acts of biological or chemical terrorism, emerging infectious diseases or other public health threats and emergencies. The role of the BOL is to provide rapid identification of etiologic agents, allowing the medical community to provide appropriate prophylaxis and or treatment to minimize morbidity and mortality.

The Laboratory Response Network (LRN) is an integrated national network of laboratories that can respond to biological or chemical public health emergencies. Established by the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories in 1999, the LRN is now a partnership between government and private organizations that have a stake in all public health threat events. The LRN comprises laboratories that follow consensus protocols developed by the CDC and the Food and Drug Administration (FDA).

All LRN testing services for the agents of bioterrorism and for emerging infectious diseases in Michigan are performed at the MDHHS BOL in Lansing. Regional public health laboratories located in Kalamazoo, Grand Rapids, Pontiac, and Saginaw provide support to local disease outbreak investigations and possible bioterrorism incidents. They work with local hospital laboratories to facilitate the transport to and testing of specimens at MDHHS.

For a directory of the Michigan Regional and LRN reference Laboratories see page 20 of this guide.

A. Authorization and Obligation to Report

1. Physicians and laboratories

The Department reviews, maintains, and publishes a list of reportable diseases and infections at least annually. The most recent version of the list can be found at: www.michigan.gov/cdinfo.

Both physicians and laboratory directors (or their designees) **must** report the suspected or confirmed existence of any disease listed in the tables on pages 6 and 11, or the unusual occurrence, outbreak, or epidemic of any disease, infection, or condition that threatens public health (e.g., norovirus or influenza outbreaks). Physicians and laboratory directors (or their designees) may also report any disease, infection, or condition to the local health department according to their medical judgment.

When a physician or laboratory director suspects the presence of a designated condition but does not have sufficient information to confirm its presence, the physician or laboratory director **must** report the designated condition as suspect to the appropriate local health department. Upon confirmation of the designated condition, a physician or laboratory director **must** report the condition as confirmed to the appropriate local health department.

Contact the appropriate local health department for reporting best practices. See pages 19-21 for a list of local health departments and Regional/LRN laboratories contact information.

(R. 325.172; R. 325.173(1)-(6); 45 C.F.R. § 164.512)

2. Who else may report

In addition, the following individuals are specifically authorized to report to local health departments any disease, infection, or condition which poses a threat to public health: **administrators; epidemiologists; infection preventionists from health care facilities or other institutions; dentists; nurses; pharmacists; physician assistants; veterinarians; and any other health care professional**. All persons with reporting responsibilities should verify that reporting systems are in place at the medical practices and hospitals in which they work, and at the laboratories they use.

Furthermore, health facility infection control committees or designees **must** develop policies and procedures to ensure appropriate reporting by both physicians who treat individuals at their facilities and by laboratories of such facilities.

(R. 325.173 (7), (8))

3. Schools, daycares and camps

Primary schools, secondary schools, preschools, camps, or child daycares **must** report to their local health department the suspected occurrence of any communicable disease listed in the table on page 6, along with any unusual occurrence, outbreak, or epidemic of any disease, infection, or condition, amongst those in attendance. Notification to the local health department should include symptoms, number of ill students and staff, affected facilities, and closings due to illness.

(R. 325.173(9))

B. How, Where, and When to Report

When reporting is required, reports **must** be made to the local health department where the patient resides, or where the service facility is located. Communicable diseases listed in the tables on pages 6 and 11 **must** be reported as soon as possible, but not later than 24 hours after diagnosis or discovery (except where otherwise noted). However, reports should be made as soon as possible. Reports may be written or oral and may be transmitted electronically. (R. 325.171(1)(a); R. 325.173(1)-(6), (10))

A laboratory in Michigan that receives or processes specimens to be tested **must** report a result consistent with the presence of a listed communicable disease agent even if the testing is performed off-site. (R. 325.173(5)(b))

Note for diseases in the tables that are associated with Category A or other potential bioterrorism agents: Anyone who discovers such a disease should immediately consult the MDHHS Lansing Laboratory at (517) 335-8063, in addition to reporting the condition to the appropriate local health department. (R. 325.179a)

1. Michigan Disease Surveillance System (MDSS)

Mandatory reporting of communicable diseases can (and, whenever possible, should) be accomplished via the MDSS. The MDSS is a web-based communicable disease reporting system developed for the state of Michigan. The system:

- Facilitates coordination among local, state, and federal public health agencies
- Provides for the secure transfer, maintenance, and analysis of communicable disease surveillance information
- Addresses needs in many areas of traditional disease surveillance, emergent infectious diseases, and biological terrorism
- Promotes participation from a variety of stakeholders including public health, health care providers, and medical laboratories
- Complies with national data standards

For more information or to enroll, contact your local health department's communicable disease program, or go to: www.michigan.gov/mdss.

2. Duplicate Reporting

Please report suspected or confirmed diseases even if you believe the report is duplicative. The MDSS can de-duplicate where necessary. Over-reporting is preferable to under-reporting.

3. HIV Reporting

HIV Mandatory reporting of HIV laboratory results should be reported electronically or by arrangement with MDHHS. A case report form, MDHHS Form 1355, should also be completed by the medical provider and faxed to the Division of HIV/STI Programs, Surveillance Unit at 313-456-1580. The case report form is available at: [www.michigan.gov/documents/mdhhs/Michigan Adult HIV Confidential Case Report Form 732626 7.pdf](http://www.michigan.gov/documents/mdhhs/Michigan_Adult_HIV_Confidential_Case_Report_Form_732626_7.pdf) and instructions can be found at:

[https://www.michigan.gov/documents/mdhhs/Michigan Adult HIV Confidential Case Report Form Instructions 724837 7.pdf](https://www.michigan.gov/documents/mdhhs/Michigan_Adult_HIV_Confidential_Case_Report_Form_Instructions_724837_7.pdf)

(R. 325.173(12); MCL 333.5114)

C. Content of the Report

The HIPAA Privacy Rule allows for the disclosure of protected health information, without individual client/patient authorization, to public health authorities, who are authorized by law to collect or receive protected health information for the purpose of preventing or controlling disease. For additional information see section H.1 on page 14.

1. A physician's report **must** contain the following information about the patient:

- Full name (and parent/guardian name if patient is a minor)
- Full residential address (and current address, if different)
- Telephone number
- Date of birth and age
- Sex, race, and ethnic origin (HIV/AIDS ethnicity and country of birth, if known)
- Name of the disease, infection, or condition being reported
- Estimated onset date of the disease, infection, or condition
- Identity of the reporting person (physician name, address, phone number)
- Pertinent laboratory results
- Any other information considered by the physician to be related to the health of the public (e.g., other ill family members/contacts, food handler, group living situation, day care attendee/employee)

(R. 325.173(11); MCL 333.5114; MCL 333.5131)

2. A report of an unusual occurrence/outbreak/epidemic of a disease/infection/condition **must**, to the extent that the information is readily available, include:

- The nature of the confirmed or suspected disease, infection, or condition
- The approximate number of cases (the number exposed is requested, but not required)
- The approximate illness onset dates
- The location of the outbreak (the facility type, e.g., nursing home, day care, restaurant)

(R. 325.173(17))

3. A laboratory report **must** contain the following information about the patient:

- Full name
- Full residential address
- Telephone number
- Date of birth or age
- Sex
- The specific laboratory test, date performed, and results
- The name and address of the reporting laboratory
- The name, address, and telephone number of the person who ordered the test
- Race and ethnicity are also requested, if available

(R. 325.173(16))

D. Physician and Authorized Health Care Professional Reporting Requirements

1. The following conditions **must** be reported to the Michigan Disease Surveillance System (MDSS) or local health department **within 24 hours** if the agent is identified by clinical or laboratory diagnosis. See footnotes for exceptions.

Report the unusual occurrence, outbreak or epidemic of any disease or condition, including healthcare-associated infections.

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Acute flaccid myelitis (1) | Malaria (Plasmodium species) |
| Anaplasmosis (Anaplasma phagocytophilum) | Measles (Measles/Rubeola virus) |
| Anthrax (Bacillus anthracis and B. cereus serovar anthracis)† (4) | Melioidosis (Burkholderia pseudomallei)† (4) |
| Arboviral encephalitides, neuro- and non-neuroinvasive: Chikungunya, Eastern Equine† , Jamestown Canyon, La Crosse, Powassan, St. Louis, West Nile, Western Equine, Zika (6) | Meningitis: bacterial, viral, fungal, parasitic and amebic |
| Babesiosis (Babesia microti) | Meningococcal Disease, sterile sites (Neisseria meningitidis) (4) |
| Blastomycosis (Blastomyces dermatitidis) | Multisystem Inflammatory Syndrome in Children (MIS-C) and in Adults (MIS-A) |
| Botulism (Clostridium botulinum)† (4) | Mumps (Mumps virus) |
| Brucellosis (Brucella abortus, melitensis, suis, and canis)† (4) | Orthopox viruses†, including: Smallpox, Mpox (4) |
| Campylobacteriosis (Campylobacter species) | Pertussis (Bordetella pertussis) |
| Candidiasis (Candida auris) (4) | Plague (Yersinia pestis)† (4) |
| Carbapenemase-Producing Organisms (CPO) (4) | Polio (Poliovirus) |
| Chancroid (Haemophilus ducreyi) | Prion disease, including Creutzfeldt-Jakob Disease (CJD) |
| Chickenpox / Varicella (Varicella-zoster virus) (6) | Psittacosis (Chlamydophila psittaci) |
| Chlamydial infections (all sites – genital, rectal, and pharyngeal, Trachoma, Lymphogranuloma venereum (LGV)) (Chlamydia trachomatis) (3,6) | Q Fever (Coxiella burnetii)† (4) |
| Cholera (Vibrio cholera) (4) | Rabies (Rabies virus) (4) |
| Coccidioidomycosis (Coccidioides species) | Rabies: potential exposure and post exposure prophylaxis (PEP) |
| Coronaviruses, Novel (SARS† , MERS-CoV) (5) | Respiratory syncytial virus (RSV) pediatric mortality (<5 years of age) |
| COVID-19; including SARS-CoV-2 variant identification | Rubella (Rubella virus) (6) |
| Cronobacter sakazakii (infants < 1 year of age) (4, blood or CSF only) | Salmonellosis (Salmonella species) (5) |
| Cryptosporidiosis (Cryptosporidium species) | Shigellosis (Shigella species) (5) |
| Cyclosporiasis (Cyclospora species) (5) | Spotted Fever (Rickettsia species) |
| Dengue Fever (Dengue virus) | Staphylococcus aureus, vancomycin intermediate/ resistant (VISA (5)/VRSA (4)) |
| Diphtheria (Corynebacterium diphtheriae) (5) | Streptococcus pneumoniae, sterile sites |
| Ehrlichiosis (Ehrlichia species) | Streptococcus pyogenes, group A, sterile sites, including Streptococcal Toxic Shock Syndrome (STSS) |
| Encephalitis, viral or unspecified | Syphilis (Treponema pallidum) (for any reactive result, report all associated syphilis tests, including negative results) (6) |
| Escherichia coli, O157:H7 and all other Shiga toxin positive serotypes (5) | Tetanus (Clostridium tetani) |
| Giardiasis (Giardia species) | Toxic Shock Syndrome (non-streptococcal) (1) |
| Glanders (Burkholderia mallei)† (4) | Trichinellosis (Trichinella spiralis) |
| Gonorrhea (Neisseria gonorrhoeae) (3, 4 – isolates from sterile sites only, 6) | Tuberculosis (Mycobacterium tuberculosis complex); report preliminary and final rapid test and culture results (4) |
| Guillain-Barre Syndrome (1) | Tularemia (Francisella tularensis)† (4) |
| Haemophilus influenzae, sterile sites (5, submit isolates for serotyping for patients < 15 years of age) | Typhoid Fever (Salmonella typhi) and Paratyphoid Fever (serotypes Paratyphi A, Paratyphi B (tartrate negative), and Paratyphi C) (5) |
| Hantavirus | Vibriosis (Non-cholera Vibrio species) (5) |
| Hemolytic Uremic Syndrome (HUS) | Yellow Fever (Yellow Fever virus) |
| Hemorrhagic Fever Viruses† (4) | Yersiniosis (Non-pestis Yersinia species) (5) |
| Hepatitis A virus (IgM anti-HAV, HAV genotype) | |
| Hepatitis B virus (HBsAg, HBeAg, IgM anti-HBc, total anti-HBc, HBV NAAT, HBV genotype; report all HBsAg and anti-HBs (positive, negative, indeterminate) for children ≤ 5 years of age) (6) | |
| Hepatitis C virus (all HCV test results including positive and negative antibody, RNA, and genotype tests) (6) | |
| Histoplasmosis (Histoplasma capsulatum) | |
| HIV tests including: reactive immunoassays including all analytes (e.g., Ab/Ag, TD1/TD2, WB, EIA, IA), detection tests (e.g., VL, NAAT, p24, genotypes), CD4 counts/percents, and all tests related to perinatal exposures) (2,6) | |
| Influenza virus (weekly aggregate counts) Influenza pediatric mortality (<18 years of age), report individual cases (5) Novel influenza viruses, report individual cases (5,6) | |
| Kawasaki Disease (1) | |
| Legionellosis (Legionella species) (5) | |
| Leprosy or Hansen's Disease (Mycobacterium leprae) | |
| Leptospirosis (Leptospira species) | |
| Listeriosis (Listeria monocytogenes) (5,6) | |
| Lyme Disease (Borrelia burgdorferi) | |

LEGEND

- (1) Reporting within 3 days is required.
 - (2) Report HIV labs electronically/by arrangement & case reports by MDHHS Form 1355. Report HIV genome sequence data only as Sanger sequences, or as consensus sequences for next generation sequencing.
 - (3) Sexually transmitted infection for which expedited partner therapy is authorized. See www.michigan.gov/hivsti for details.
 - (4) A laboratory shall immediately submit **suspect or confirmed** isolates, subcultures, or specimens from the patient being tested to the MDHHS Lansing laboratory.
 - (5) Specimen and/or isolate requested. *Enteric*: If an isolate is not available from non-culture based testing, the positive broth and/or stool in transport medium must be submitted to the MDHHS Lansing laboratory. *Respiratory*: Submit specimens if available.
 - (6) Report pregnancy status
- Bold Text†**= Category A Bioterrorism or Select Agent must be notified immediately to the MDHHS Laboratory (517-335-8063)

2. Animal bites/rabies reporting

a. Animal Bite Reporting

Any person who has knowledge of an animal bite where rabies is suspected **must, within 24 hours of the biting incident**, report the bite to the appropriate local health department and to the local health department where the bite occurred. The report **must** include all the following information:

- Animal species inflicting the bite
- Animal owner's name, address, and telephone number
- Vaccination status of animal
- Date and location of biting incident
- Name, address, and telephone number of the person bitten
- Site of the bite on the body
- Name of the reporter of the bite

(R 325.182 (6))

Please report any encounter with a bat to the local health department, even where exposure is uncertain. For example, a sleeping person awakens to find a bat in the same room, or an adult witnesses a bat in a room with an unattended child, a person with an intellectual or developmental disability, or intoxicated person.

Upon request by the Department or local health department, any person (including the general public) who has information regarding the identity, whereabouts, or vaccination status of an animal that has bitten an individual or otherwise potentially exposed an individual to rabies, or information about the owner of the animal, **must** provide information about the animal or the animal's owner to the local health department or MDHHS. (R 325.182 (7))

An animal that has bitten an individual or otherwise potentially exposed an individual to rabies **must** be handled pursuant to the provisions of the publication entitled "Compendium of Animal Rabies Control" issued by the National Association of State Public Health Veterinarians. Copies of this publication are available online at: www.michigan.gov/rabies. (R 325.182 (5))

b. Rabies Post-exposure Prophylaxis (RPEP) Reporting

Healthcare providers/healthcare facilities are required to report to Michigan local health departments any initiation of rabies post-exposure prophylaxis to an individual exposed or potentially exposed to rabies, whether through a bite or other type of exposure (e.g., a person wakes to a bat in the room where they were sleeping, bat found in the room with a child, or adult who cannot account for their time in the room with the bat). In addition to the patient information listed in Section C. 1. (Content of the Report) above, the report must also contain the following:

- Date, location, and description of the exposure incident
- Animal species involved in the exposure (e.g., bat, dog, horse)
- Disposition of the exposing animal (e.g., alive, dead, escaped, available for observation, sent for rabies diagnostic testing)
- Treatments initiated (e.g., wound treatment, tetanus immunization, rabies immune globulin administration, rabies vaccine administration) and each subsequent rabies vaccine dose administered in the series.

The initiation of RPEP is a medical urgency, not an emergency. Before initiating treatment, healthcare providers should consider the rabies risk for each situation, including whether the exposing animal might be available for observation or testing. Prompt reporting of animal bites and potential rabies exposures to local authorities aids the investigation into animals that have potentially exposed people to rabies. In many cases, treatment of the exposed person can wait for the outcome of the animal investigation. (R. 325.180 (5))

c. Suspect Human Rabies Case Diagnostic Testing

A physician who performs a postmortem on the body of a person who died of rabies or who was suspected of dying of rabies **must** immediately submit non-preserved portions of the hippocampus major and spinal cord to the MDHHS Laboratory for rabies examination. A written history of the case **must** accompany the specimens. (R. 325.180 (4))

3. Influenza reporting

Individual reports are required **within 24 hours** when influenza is suspected to have caused or contributed to mortality in a person aged less than 18 years, or if the infected individual traveled outside of North America within the 2 weeks prior to symptom onset. Otherwise, aggregate reporting is required. (R. 325.173 (15))

4. Pregnancy status reporting and HIV and STI testing

Pregnancy status, **must** be reported for certain conditions. Please refer to the lists on pages 6 and 11 for reporting requirements.

Physicians or other individuals authorized by law to provide medical treatment to pregnant women **must**, at the time of the woman's initial examination and during the third trimester, collect clinical specimens and submit those to a laboratory for sexually transmitted infection testing including, HIV or an antibody to HIV and hepatitis B.

Where it appears that testing was not performed during pregnancy, the aforementioned testing **must** be performed at the time of delivery, or when the mother seeks treatment in the immediate postpartum period after having recently delivered an infant outside of a health care facility. This testing should not be performed where the mother does not consent to testing or where testing is medically inadvisable.

(MCL 333.5123(1), (2), (3))

E. Expedited Partner Therapy

Expedited Partner Therapy (EPT) allows clinicians to provide patients with medication or a prescription to deliver to their sex partner(s) without a medical evaluation or clinical assessment of those partners. To curtail transmission and reduce reinfection rates of STIs, clinicians are encouraged to utilize EPT as an additional strategy for partner management and treatment. Expedited Partner Therapy is a strategy to assure individuals exposed to select STIs are provided timely and appropriate antibiotic treatment.

Patients most appropriate for EPT are those with partners who are unable or unlikely to seek prompt clinical service. The number of doses is limited to the number of known sex partners in the previous 60 days; or the most recent sex partner prior to the previous 60 days. Along with medication, EPT must include information that encourages the recipient to seek follow-up care and testing as soon as possible.

EPT should **not** be used for the following:

- STI/HIV co-infections
- For patients co-infected with treatable STIs, other than chlamydia or gonorrhea
- Cases of suspected child abuse or sexual assault
- Situations where a patient's safety is in question
- For partners with known allergies to antibiotics

MDHHS routinely reviews and updates Michigan's EPT guidance. Providers are encouraged to visit the MDHHS/DHSP website for the most up to date guidelines, directives, and patient education materials: www.michigan.gov/hivsti.

(MCL 333.5110)

F. Immunization Requirements and Reporting

1. Michigan vaccination requirements

The MDHHS and all local health departments in Michigan support immunization as guided by the federal Advisory Committee on Immunization Practices (ACIP). Compliance with current ACIP recommendations generally fulfills all minimum legal requirements for routine vaccination in Michigan.

2. Michigan vaccine programs

Michigan physicians may obtain many childhood vaccines for patients meeting specific eligibility requirements through their local health department by participating in the Vaccines for Children Program. Health care providers who see adults that are uninsured or underinsured for vaccines should refer patients to the local health department for possible eligibility to receive Tdap, Td, MMR, Shingles, HPV, Pneumococcal, Hepatitis A, and Hepatitis B vaccines, if indicated, at little to no cost. Hepatitis B vaccine is available to all birthing hospitals to administer the first dose of Hepatitis B vaccine to all babies immediately after birth.

3. Reporting to the Michigan Care Improvement Registry

The Michigan Care Improvement Registry (MCIR), formerly known as the Michigan Childhood Immunization Registry, is an electronic database accessible to all enrolled physicians and clinics in the state. It was established to provide a single location for Michigan immunization records so that a complete record can be maintained even if a person received vaccines from multiple providers. By law, persons who administer vaccines **must** report to the Department all immunizations administered to a person who is less than 20 years of age. Providers are strongly encouraged to submit immunization information for all individuals, regardless of age, to the MCIR. A person can provide written notice that they do not wish their or their child's immunization information to be reported to the MCIR. Access to the MCIR is restricted and all users **must** obtain authorization along with a user ID and a password. The MCIR can provide an official immunization record, an assessment of a person's immunization status with a forecast of future doses needed, and an assessment of a clinic population. More information about the MCIR is available at: <http://www.mcir.org>

(R. 325.163)

4. School and childcare immunization requirements

All children **must** have a complete immunization record or a signed waiver if enrolled in a licensed childcare center, camp, or enrolled in kindergarten, 7th grade, or transferred new to the school district. For a listing of required vaccines for school and childcare please visit the website listed below (then click on the links for Local Health Departments > Immunization Waiver Information and scroll to Vaccines Required for School or Child Care).

Parents or guardians who want to claim a non-medical waiver to receive education from a local health department about the benefits of vaccination and the risks of vaccine-preventable diseases before claiming the waiver (R. 325.176 (12)). More information can be found at: <http://www.michigan.gov/immunize>.

(R. 325.176)

G. Laboratory Reporting Requirements

1. The following conditions **must** be reported to the Michigan Disease Surveillance System (MDSS) or local health department **within 24 hours** if the agent is identified by clinical or laboratory diagnosis. See footnotes for exceptions.

Report the unusual occurrence, outbreak or epidemic of any disease or condition, including healthcare-associated infections.

| | |
|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Acute flaccid myelitis (1) | Listeria monocytogenes (Listeriosis) (5,6) |
| Anaplasma phagocytophilum (Anaplasmosis) | Measles virus (Measles/Rubeola) |
| Arboviral encephalitides, neuro- and non-neuroinvasive: | Meningitis: bacterial, viral, fungal, parasitic, and amebic |
| Chikungunya, Eastern Equine† , Jamestown Canyon, La Crosse, | Multisystem Inflammatory Syndrome in Children (MIS-C) and in |
| Powassan, St. Louis, West Nile, Western Equine, Zika (6) | Adults (MIS-A) |
| Babesia microti (Babesiosis) | Mumps virus |
| Bacillus anthracis and B. cereus serovar anthracis (Anthrax)† (4) | Mycobacterium leprae (Leprosy or Hansen's Disease) |
| Blastomyces dermatitidis (Blastomycosis) | Mycobacterium tuberculosis complex (Tuberculosis); |
| Bordetella pertussis (Pertussis) | report preliminary and final rapid test and culture results (4) |
| Borrelia burgdorferi (Lyme Disease) | Neisseria gonorrhoeae (Gonorrhea) (3, 4 – isolates from sterile sites |
| Brucella abortus, melitensis, suis, and canis (Brucellosis)† (4) | only, 6) |
| Burkholderia mallei (Glanders)† (4) | Neisseria meningitidis, sterile sites (Meningococcal Disease) (4) |
| Burkholderia pseudomallei (Melioidosis)† (4) | Orthopox viruses†, including: Smallpox, Mpox (4) |
| Campylobacter species (Campylobacteriosis) | Plasmodium species (Malaria) |
| Candida auris (Candidiasis) (4) | Poliovirus (Polio) |
| Carbapenemase-Producing Organisms (CPO) (4) | Prion disease, including Creutzfeldt-Jakob Disease (CJD) |
| Chlamydia trachomatis (infections at all sites – genital, rectal, and | Rabies virus (4) |
| pharyngeal, Trachoma, Lymphogranuloma venereum (LGV)) (3,6) | Rabies: potential exposure and post exposure prophylaxis (PEP) |
| Chlamydophila psittaci (Psittacosis) | Respiratory syncytial virus (RSV) pediatric mortality (< 5 years of age) |
| Clostridium botulinum (Botulism)† (4) | Rickettsia species (Spotted Fever) |
| Clostridium tetani (Tetanus) | Rubella virus (6) |
| Coccidioides species (Coccidioidomycosis) | Salmonella species (Salmonellosis) (5) |
| Coronaviruses, Novel (SARS† , MERS-CoV) (5) | Salmonella Paratyphi (Paratyphoid Fever): serotypes Paratyphi A, |
| Corynebacterium diphtheriae (Diphtheria) (5) | Paratyphi B (tartrate negative), and Paratyphi C (5) |
| Coxiella burnetii (Q Fever)† (4) | Salmonella typhi (Typhoid Fever) (5) |
| Cronobacter sakazakii (infants < 1 year of age) (4, blood or CSF only) | SARS-CoV-2 virus (COVID-19); including variant identification |
| Cryptosporidium species (Cryptosporidiosis) | Shigella species (Shigellosis) (5) |
| Cyclospora species (Cyclosporiasis) (5) | Staphylococcus aureus Toxic Shock Syndrome (1) |
| Dengue virus (Dengue Fever) | Staphylococcus aureus, vancomycin intermediate/ resistant (VISA (5)/VRSA (4)) |
| Ehrlichia species (Ehrlichiosis) | Streptococcus pneumoniae, sterile sites |
| Encephalitis, viral or unspecified | Streptococcus pyogenes, group A, sterile sites, including |
| Escherichia coli, O157:H7 and all other Shiga toxin positive | Streptococcal Toxic Shock Syndrome (STSS) |
| serotypes (including HUS) (5) | Treponema pallidum (Syphilis) (for any reactive result, report all |
| Francisella tularensis (Tularemia)† (4) | associated syphilis tests, including negative results) (6) |
| Giardia species (Giardiasis) | Trichinella spiralis (Trichinellosis) |
| Guillain-Barre Syndrome (1) | Varicella-zoster virus (Chickenpox) (6) |
| Haemophilus ducreyi (Chancroid) | Vibrio cholera (Cholera) (4) |
| Haemophilus influenzae, sterile sites (5, submit isolates | Vibrio species (Vibriosis: non-cholera species) (5) |
| for serotyping for patients <15 years of age) | Yellow fever virus |
| Hantavirus | Yersinia species (Yersiniosis: non-pestis species) (5) |
| Hemorrhagic Fever Viruses† (4) | Yersinia pestis (Plague)† (4) |
| Hepatitis A virus (IgM anti-HAV, HAV genotype) | |
| Hepatitis B virus (HBsAg, HBeAg, IgM anti-HBc, total anti-HBc, HBV NAAT, | |
| HBV genotype; report all HBsAg and anti-HBs (positive, negative, | |
| indeterminate) for children ≤ 5 years of age) (6) | |
| Hepatitis C virus (all HCV test results including positive and negative | |
| antibody, RNA, and genotype tests) (6) | |
| Histoplasma capsulatum (Histoplasmosis) | |
| HIV tests including: reactive immunoassays including all analytes (e.g., | |
| Ab/Ag, TD1/TD2, WB, EIA, IA), detection tests (e.g., VL, NAAT, p24, | |
| genotypes), CD4 counts/percents; and all tests related to perinatal | |
| exposures) (2,6) | |
| Influenza virus (weekly aggregate counts) | |
| Influenza pediatric mortality (<18 years of age), report individual cases (5) | |
| Novel influenza viruses, report individual cases (5,6) | |
| Kawasaki Disease (1) | |
| Legionella species (Legionellosis) (5) | |
| Leptospira species (Leptospirosis) | |

LEGEND

- (1) Reporting within 3 days is required.
 - (2) Report HIV labs electronically/by arrangement & case reports by MDHHS Form 1355. Report HIV genome sequence data only as Sanger sequences, or as consensus sequences for next generation sequencing.
 - (3) Sexually transmitted infection for which expedited partner therapy is authorized. See www.michigan.gov/hivsti for details.
 - (4) A laboratory shall immediately submit **suspect or confirmed** isolates, subcultures, or specimens from the patient being tested to the MDHHS Lansing laboratory.
 - (5) Specimen and/or isolate requested. *Enteric*: If an isolate is not available from non-culture based testing, the positive broth and/or stool in transport medium must be submitted to the MDHHS Lansing laboratory. *Respiratory*: Submit specimens if available.
 - (6) Report pregnancy status
- Bold Text†**= Category A Bioterrorism or Select Agent must be notified immediately to the MDHHS Laboratory (517-335-8063)

2. Carbapenemase-Producing Organisms (CPO): Any Enterobacterales¹, *Pseudomonas aeruginosa*, or *Acinetobacter* spp. organism, or culture-independent test)

- a. Physicians and Laboratories **must report** an isolate or specimen meeting any of the following:
- Positive phenotypic test² result for carbapenemase production
 - Positive molecular³ test result detecting a carbapenemase gene⁴ (with or without organism identification)
 - Detection of carbapenemase gene⁴ by next generation sequencing (NGS)
- b. Laboratories **must submit all CPO isolates** to the MDHHS Bureau of Laboratories (BOL) Lansing laboratory for antimicrobial resistance confirmation (ARC) testing.

If laboratories are unable to detect CPOs (i.e., cannot test for carbapenemase production or carbapenemase genes), any Enterobacterales¹, *Pseudomonas aeruginosa*, or *Acinetobacter* spp. isolate demonstrating resistance profiles defined below should be submitted to the MDHHS BOL Lansing laboratory for further testing. Clinical laboratories should follow Clinical and Laboratory Standards Institute (CLSI) guidance (M100) regarding which antimicrobials should be tested for each organism and minimum inhibitory concentration (MIC) breakpoints for each antimicrobial tested.

Carbapenem-resistant Enterobacterales¹ (CRE) isolate submissions:

- Any isolate with an MIC of ≥ 4 $\mu\text{g/mL}$ for doripenem, imipenem, or meropenem, or ≥ 2 $\mu\text{g/mL}$ for ertapenem
 - *Morganella*, *Proteus*, *Providencia* spp. may have intrinsic resistance to imipenem. Only those isolates that are resistant to one or more carbapenems other than imipenem should be submitted.
- Any isolate that is non-susceptible to all antibiotics tested

Carbapenem-resistant *Pseudomonas aeruginosa* isolate submissions:

- Any isolate with:
 - An MIC of ≥ 8 $\mu\text{g/mL}$ to doripenem, imipenem, or meropenem AND
 - An MIC of ≥ 16 $\mu\text{g/mL}$ to cefepime or ceftazidime
- Any isolate that is non-susceptible to all antibiotics tested

Carbapenem-resistant *Acinetobacter* spp. isolate submissions:

- Any isolate with an MIC of ≥ 8 $\mu\text{g/mL}$ for doripenem, imipenem, or meropenem
- Any isolate that is non-susceptible to all antibiotics tested

If a CPO is detected via a molecular test directly from a clinical specimen, perform a culture to obtain the bacterial isolate and perform subsequent testing to determine carbapenemase production or carbapenemase gene, and antibiotic susceptibility profile when possible, and submit isolate.

¹Enterobacterales includes but is not limited to the genera *Escherichia*, *Klebsiella*, *Enterobacter*, *Citrobacter*, *Morganella*, *Proteus*, *Providencia*, *Raoultella*, *Serratia*, *Hafnia*, and others.

²Phenotypic tests for carbapenemase production detection include, but are not limited to:

- Carba NP
- Metallo- β -lactamase testing (e.g., E-test)
- Modified Carbapenem Inactivation Method (mCIM) or EDTA-Modified Carbapenem Inactivation Method (eCIM)
- Carbapenem Inactivation Method (CIM)
- Immunochromatography tests (ICT)

- Isolates positive for phenotypic carbapenemase production but negative by molecular tests for known carbapenemase genes should still be reported and submitted

³Molecular tests for carbapenemase gene detection include, but are not limited to:

- Cepheid Xpert Carba-R®
- Nanosphere Verigene BC-GN®
- EPlex® BCID GN Panel
- FilmArray™ BCID
- FilmArray™ pneumonia panel
- BD MAX™ Check-Points
- Streck ARM-D
- Validated, laboratory-developed NAAT (e.g., PCR)

⁴Common carbapenemase genes include bla_{KPC}, bla_{NDM}, bla_{VIM}, bla_{IMP}, bla_{OXA-48-like}, but other genes may include but are not limited to bla_{SIM}, bla_{GIM}, bla_{SPM}, other bla_{OXA}, genes

3. Mycobacterium tuberculosis complex reporting and culture submission

A laboratory that receives a specimen from an individual that results in a laboratory report of *Mycobacterium tuberculosis* complex or yields a preliminary result* indicative of *Mycobacterium tuberculosis* complex is responsible for ensuring submission of the following:

- To the appropriate local health department – report all results and interpretations of those results.
- To the MDHHS Laboratory – the first *Mycobacterium tuberculosis* complex isolate, AND any *Mycobacterium tuberculosis* complex isolate or subculture thereof from a follow-up specimen collected 90 days or more after the collection of the first *Mycobacterium tuberculosis* complex-positive specimen.

**"Preliminary result" includes, but is not limited to, results from nucleic acid amplification tests, or other genetic probe tests, chromatographic or other such tests that may be performed prior to final culture identification of a clinical specimen. (R. 325.179)*

4. Rabies examination and reporting

A laboratory in this state that conducts examinations of animals for rabies **must** report all the following information to MDHHS within 7 days after examination. If a sample is being submitted to the MDHHS laboratory for examination the following information **must** be submitted along with the sample:

- Species of animal, anatomic site of exposure, and vaccine history, if appropriate
- Name and address of the owner of the animal
- Name, address, and 24/7 phone number of the person or agency submitting the specimen
- Name, address, and home phone number of the person exposed to the animal examined or the owner of the pet exposed to the animal examined
- Date and results of the examination

(R. 325.180)

5. Viral hepatitis reporting

*Note: Every new reportable result should be reported, regardless of whether the patient has been previously reported. Laboratories and physicians **must** report the following viral hepatitis tests to the appropriate local health department within 24 hours:*

Hepatitis A virus (HAV)

Report all positive:

- IgM antibodies to HAV (IgM anti-HAV)
- HAV genotype

Hepatitis B virus (HBV)

Report all (positive, negative, and indeterminate) for **children 5 years of age and younger**:

- Hepatitis B Surface Antigen (HBsAg)
- Antibodies to Hepatitis B Surface Antigen (Anti-HBs)

Report all positive (for individuals 6 years of age and older):

- HBsAg
- Hepatitis B e antigen (HBeAg)
- IgM antibody to Hepatitis B Core Antigen (IgM anti-HBc)
- Total antibody to Hepatitis B Core Antigen (total anti-HBc)
- HBV Nucleic Acid Tests:
 - Quantitative HBV DNA (viral load)
 - Qualitative HBV DNA
 - HBV genotype
- **Report pregnancy status**

**If pregnant, please refer to the Perinatal Hepatitis B Prevention Program (PHBPP). The PHBPP's electronic fax is 517-763-0470.*

Hepatitis C virus (HCV)

Report all positive AND negative**:

- Hepatitis C Virus Antibody Tests (anti-HCV)
- Hepatitis Nucleic Acid Tests:
 - HCV Quantitative RNA results (viral load)
 - HCV Qualitative RNA results
 - HCV genotype
- Hepatitis C Antigen Tests
- **Report pregnancy status**

***Negative HCV lab results are only required to be reported by entities submitting to MDSS via HL7 electronic laboratory reporting (ELR)*

6. Submission of other designated conditions specimens

a. The first isolate, subculture (or specimen where appropriate) from the patient being tested to be sent to the MDHHS Lansing Laboratory:

| Submit suspect isolates or specimens that contain any of the following to the MDHHS Lansing Laboratory* | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Bacillus anthracis</i> and <i>B. cereus</i> serovar <i>anthracis</i> <i>Brucella abortus</i> , <i>melitensis</i> , <i>suis</i> , and <i>canis</i> <i>Burkholderia mallei</i> <i>Burkholderia pseudomallei</i> <i>Candida auris</i> Carbapenemase-Producing Organisms (CPO) <i>Clostridium botulinum</i> Coronaviruses (SARS and MERS-CoV) <i>Corynebacterium diphtheriae</i> <i>Coxiella burnetii</i> <i>Cyclospora</i> species <i>Escherichia coli</i> O157:H7 and all other shiga toxin positive serotypes <i>Francisella tularensis</i> <i>Haemophilus influenzae</i> (sterile sites only; submit isolates for serotyping for patients <15 years old) Hemorrhagic fever viruses Influenza (novel strains or pediatric mortality <18 years of age) | <i>Legionella</i> species <i>Listeria monocytogenes</i> <i>Mycobacterium tuberculosis</i> complex <i>Neisseria gonorrhoeae</i> - isolate collected from a sterile site <i>Neisseria meningitidis</i> - isolate collected from a sterile site Orthopox viruses (including smallpox and mpox) Rabies <i>Salmonella</i> species, including <i>Typhi</i> <i>Shigella</i> species <i>Staphylococcus aureus</i> (only vancomycin intermediate and resistant (VISA/VRSA)) <i>Vibrio cholera</i> , <i>V. parahaemolyticus</i> , <i>V. vulnificus</i> , <i>Photobacterium damsela</i> ssp. <i>Damsela</i> , or <i>Grimontia hollisae</i> <i>Yersinia pestis</i> and non- <i>pestis</i> species |

*Refer to reportable disease lists on pages 6 and 11 for specimen submission requirements.

(R. 325.179a)

b. Other specimen submission

For unexplained/unusual deaths, deaths related to pediatric influenza, or suspected cases of prion disease such as Creutzfeldt-Jakob disease, please contact the local health department and the MDHHS Communicable Disease Section for available testing facilities, specimen collection, and sample requirements information.

H. Investigative Authority of Public Health Departments

1. Access to information

The Privacy Rule in HIPAA allows for the disclosure of protected health information, without individual client/patient authorization, to public health authorities, who are authorized by law to collect or receive protected health information for the purpose of preventing or controlling disease. (45 C.F.R. § 164.512(b)(1)(i))

In addition, the Michigan Public Health Code and administrative rules give the local and state health departments the authority and responsibility to investigate cases of disease and suspect transmission, including the review of medical records. An investigator who presents official identification of a local health department or the MDHHS **must** be provided with medical and epidemiologic information pertaining to any of the following persons on request:

- Individuals who have any condition required to be reported or other condition of public health significance
- Individuals, whether ill or well, who are part of a group in which an unusual occurrence, outbreak, or epidemic has occurred
- Individuals who are not known to have a condition, but whose medical or epidemiological information is needed for investigation into the cause of a condition of public health importance
- Individuals potentially exposed to a designated condition
- Individuals who may be a carrier or health threat to others under MCL 333.5201
- Any other information that may be relevant to an investigation

(R. 325.174(2))

2. Assistance and support

State and local health departments have the authority to contact physicians, laboratories, infection control preventionists and patients to collect information to help them determine if a community outbreak is occurring; to identify, test and provide prophylaxis to household or other contacts; and, perhaps most importantly, to provide information to help prevent the spread of communicable diseases. The assistance and support of health care providers is invaluable.

(R. 325.174; MCL 333.2231; MCL 333.2237(1); MCL 333.5111(2)(a)-(d))

3. Validation of reporting

Requests for individual medical and epidemiological information to validate the completeness and accuracy of reporting are specifically authorized. Information released in response to a request made by type of disease, infection, or condition or diagnostic code category may include information about individuals who are not the focus of the request if it is not reasonably possible to delete their information from the requested information. (R. 325.174(3))

4. Information to be provided

Medical and epidemiological information means any of the following, in detail:

- Medical histories
- Examination results
- Findings of all associated laboratory tests
- Diagnoses
- Treatments employed
- Outcomes
- Description and source of suspected causative agents
- Any other pertinent information that is requested by the state or local public health authority in the course of an investigation

(R. 325.171(h))

5. Authority to investigate

The Department may inspect, investigate, or authorize an inspection or investigation to be made of any matter, thing, premises, place, person, record, vehicle, incident, or event, and may apply for an inspection or investigation warrant.

A representative of the local health department or the MDHHS may obtain human, animal, environmental, or other types of specimens or cause such specimens to be obtained by appropriate means (and, where necessary, upon obtaining an appropriate warrant), including venipuncture, in the course of an investigation of a reported disease, infection, or condition.

(MCL 333.2241; R. 325.174)

I. Confidentiality

Medical and epidemiological information that identifies an individual and that is gathered in connection with an investigation is confidential and is not open to public inspection without the individual's consent or the consent of the individual's guardian, unless public inspection is necessary to protect the public health as determined by a local health officer or the director of MDHHS. (R. 325.181(2))

HIPAA permits disclosure of protected health information to a public health authority (including the Department and local health departments) “for the purpose of preventing or controlling disease, injury, or disability, including, but not limited to, the reporting of disease, injury, vital events such as birth or death, and the conduct of public health surveillance, public health investigations, and public health interventions; or, at the direction of a public health authority, to an official of a foreign government agency that is acting in collaboration with a public health authority.” (45 C.F.R. § 164.512(b))

J. Isolation and Other Preventive Measures

A physician or other person attending a case of communicable disease **must** arrange for appropriate barrier precautions, prophylactic treatment, or isolation, if needed to prevent the spread of disease to other household members, patients, or to the community. Provision of information and prophylactic treatment to at-risk contacts, as appropriate, to prevent secondary spread is extremely important.

A physician or person who seeks information on appropriate precautionary measures may request the local health department or the MDHHS to provide the necessary information. The local health officer or the MDHHS may institute appropriate isolation or other barrier precautions for a case or a suspected case of disease, infection, or other condition as necessary to protect the public’s health.

(R. 325.175(1))

K. Exclusion From School

When school officials or local health department staff or personnel reasonably suspect that a student has a communicable condition (except HIV or AIDS), they may exclude the student for a period of time sufficient to obtain a determination by a physician or health officer as to the presence of the condition. Individuals who have incomplete immunizations may be excluded from a school or childcare center if a vaccine preventable disease is either confirmed or suspected in the program. A student may return to school when it is determined that he or she no longer represents a communicable disease risk to other students.

Note: There are provisions in the public health code relating to the non-exclusion of those with HIV infections or AIDS. An authorized representative of the Department or a local health officer may disclose information pertaining to an individual who is HIV infected or has been diagnosed as having AIDS if the disclosure is necessary to prevent a reasonably foreseeable risk of transmission of HIV to pupils in the school district. Check with your local health department or legal counsel if you need more information.

(R. 325.175(2)-(4); MCL 333.5131(5)(c))

Consultation Service and Bibliography

All local health departments are required under the public health code to have a Michigan-licensed physician medical director on staff (R. 325.13002). In addition, some local health departments employ one or more epidemiologists or other communicable disease specialists. Health care professionals are encouraged to consult with these individuals whenever they have questions concerning any issues that may be related to the maintenance of the health of the public. There are a number of related (and generally inexpensive) reference works that provide good information regarding the prevention and control of communicable disease that may be of interest and use to Michigan health care providers. Because these recommendations change as new treatments, vaccines and knowledge become available, a current edition should be consulted. These reference works include:

***Control of Communicable Diseases Manual
21st Edition, 2022***

An Official Report of the American Public Health Association
David L. Heymann, MD, Editor
American Public Health Association
www.apha.org/ccdm

***Report of the Committee on Infectious Disease
of the American Academy of Pediatrics (Red
Book), 2021***

American Academy of Pediatrics
141 Northwest Point Blvd.
Elk Grove, Illinois 60009
redbook.solutions.aap.org/

***CDC Advisory Committee on Immunization
Practices (ACIP)***

www.cdc.gov/vaccines/acip/

***CDC Epidemiology and Prevention of Vaccine-
Preventable Diseases (Pink Book), 14th Edition,
2021***

www.cdc.gov/vaccines/pubs/pinkbook/index.html

***CDC Case definitions for infectious conditions
under public health surveillance***

www.cdc.gov/nndss

***CDC Morbidity and Mortality Weekly Report
(MMWR)***

www.cdc.gov/mmwr/index.html

CDC Health Information for International Travel

wwwnc.cdc.gov/travel/

CDC Isolation Precautions

<http://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html>

***Compendium of Animal Rabies Prevention and
Control (Current)***

National Association of State Public Health
Veterinarians
www.nasphv.org/documentsCompendia.html

***Compendium of Measures to Prevent Disease
Associated with Animals in Public Settings
(Current)***

National Association of State Public Health
Veterinarians
nasphv.org/documentsCompendiumAnimals.html

CDC Emerging Infectious Diseases Journal

wwwnc.cdc.gov/eid/

Other guidelines and references may be available to physicians through the MDHHS or local health department on such topics as: the U.S. Public Health Service guidelines for hepatitis vaccination and prophylaxis, the ACIP recommendations on adult immunizations, foreign travel guidelines, etc.

Important Websites

Centers for Disease Control and Prevention (CDC)

www.cdc.gov

Michigan Department of Health and Human Services (MDHHS)

www.michigan.gov/mdhhs

MDHHS Bureau of Laboratories Information

www.michigan.gov/mdhhs/department/laboratory

MDHHS Communicable Disease Information

www.michigan.gov/cdinfo

Michigan Disease Surveillance System

www.michigan.gov/mdss

MDHHS Division of Immunization Information

www.michigan.gov/immunize

Michigan Care Improvement Registry

www.mcir.org

Michigan Emerging Diseases

www.michigan.gov/emergingdiseases

Michigan Healthcare-Associated Infection Surveillance and Prevention

www.michigan.gov/hai

MDHHS Hepatitis Program

www.michigan.gov/hepatitis

Michigan HIV, STI, Expedited Partner Therapy, and Hepatitis Information

www.michigan.gov/hivsti

Michigan Influenza

www.michigan.gov/influenza

MDHHS Tuberculosis Program

www.michigan.gov/tb

Michigan Administrative code

www.michigan.gov/opt

Michigan Compiled Laws

www.legislature.mi.gov

Michigan Association for Local Public Health (MALPH)

www.malph.org

Directory of the Michigan Public Health Laboratories

| |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| State Public Health Laboratory |
| <p>Michigan Department of Health and Human Services Laboratory P.O. Box 30035 3350 N. Martin Luther King Jr. Blvd. Lansing, MI 48909 (517) 335-8063</p> |
| Local Health Department Regional Laboratories |
| <p>Oakland County Health Division Laboratory (1) 1200 N Telegraph Road, Bldg 32E Pontiac, MI 48341 (248) 858-1310</p> |
| <p>Saginaw County Health Department Laboratory (1) 1600 North Michigan Avenue Saginaw, MI 48602 (989) 758-3825</p> |
| <p>Kalamazoo County Health & Community Services Laboratory (1) 311 East Alcott Street Kalamazoo, MI 49001 (269) 373-5360</p> |
| <p>Health Department of Northwest Michigan Laboratory (1) 95 Livingston Blvd Gaylord, MI 49735 (989) 732-6879</p> |
| <p>LMAS District Health Department Laboratory (1) 14150 Hamilton Lake Rd Newberry, MI 49868 (906) 293-5107, ext. 363</p> |
| <p>Western U. P. Health Department Laboratory (1) 540 Depot St. Hancock, MI 49930 (906) 482-7382, ext. 150</p> |

(1) These laboratories provide consultation and facilitate the transport of isolates/specimens to MDHHS. They perform no LRN testing.

NOTE: The Regional Laboratories offer a collection of diagnostic testing. Individual location test directories are available from each location.

DIRECTORY OF MICHIGAN HEALTH DEPARTMENTS BY COUNTY PAGE 1

In general, health care providers should seek consultation regarding communicable disease prevention and control services through their local health departments.

Please check your local phone directory or health department website to see if there is a branch office in your community. Write that number here: _____

| COUNTY | HEALTH DEPT. | CO. OFFICE | AREA | PHONE | FAX |
|--------------|-----------------------|------------------|------|--------------|--------------|
| Alcona | District 2 | Harrisville | 989 | 724-6757 | 343-1896 |
| Alger | LMAS DHD | Munising | 906 | 387-2297 | 387-2224 |
| Allegan | Allegan County | Allegan | 269 | 673-5411 | 673-2163 |
| Alpena | District 4 | Alpena | 989 | 356-4507 | 356-3529 |
| Antrim | Health Dept. of NW MI | Bellaire | 800 | 432-4121 | 231-547-6238 |
| Arenac | Cent MI DHD | Standish | 989 | 846-6541 | 846-0431 |
| Baraga | Western UP Dist | L'Anse | 906 | 524-6142 | 524-6144 |
| Barry | Barry-Eaton DHD | Hastings | 517 | 541-2641 | 541-2666 |
| Bay | Bay County | Bay City | 989 | 895-2039 | 895-2083 |
| Benzie | Benzie-Leelanau DHD | Benzonia | 231 | 882-4409 | 882-0143 |
| Berrien | Berrien County | Benton Harbor | 269 | 926-7121 | 926-8129 |
| Branch | Branch/Hills/St Jo | Coldwater | 517 | 279-9561x105 | 278-2923 |
| Calhoun | Calhoun County | Battle Creek | 269 | 969-6370 | 969-6488 |
| Cass | Van Buren-Cass DHD | Dowagiac | 269 | 782-0064 | 782-0121 |
| Charlevoix | Health Dept. of NW MI | Charlevoix | 800 | 432-4121 | 231-547-6238 |
| Cheboygan | District 4 | Cheboygan | 231 | 627-8850 | 627-9466 |
| Chippewa | Chippewa County | Sault Ste. Marie | 906 | 635-1566 | 635-7081 |
| Clare | Cent MI DHD | Harrison | 989 | 539-6731 | 539-4449 |
| Clinton | Mid-MI DHD | St. Johns | 989 | 227-3111 | 227-3126 |
| Crawford | District 10 | Grayling | 989 | 348-7800 | 348-5346 |
| Delta | Delta-Men Dist | Escanaba | 906 | 786-4111 | 789-8148 |
| Dickinson | Dick-Iron Dist | Kingsford | 906 | 774-1868 | 779-7232 |
| Eaton | Barry-Eaton DHD | Charlotte | 517 | 541-2641 | 541-2666 |
| Emmet | Health Dept. of NW MI | Petoskey | 800 | 432-4121 | 231-547-6238 |
| Genesee | Genesee County | Flint | 810 | 257-1017 | 257-3247 |
| Gladwin | Cent MI DHD | Gladwin | 989 | 426-9431 | 426-6952 |
| Gogebic | Western UP Dist | Bessemer | 906 | 667-0200 | 667-0020 |
| Gd. Traverse | Grand Traverse Co | Traverse City | 231 | 995-6125 | 995-6126 |
| Graiot | Mid-MI DHD | Ithaca | 989 | 875-1019 | 875-1032 |
| Hillsdale | Branch/Hills/St Jo | Hillsdale | 517 | 437-7395x307 | 437-0166 |
| Houghton | Western UP Dist | Hancock | 906 | 482-7382 | 482-9410 |
| Huron | Huron County | Bad Axe | 989 | 269-9721 | 269-4181 |
| Ingham | Ingham County | Lansing | 517 | 887-4308 | 887-4379 |
| Ionia | Ionia County | Ionia | 616 | 527-5341 | 527-8208 |
| Iosco | District 2 | Tawas City | 989 | 362-6183 | 343-1896 |
| Iron | Dick-Iron Dist | Iron River | 906 | 265-9913 | 265-4174 |
| Isabella | Cent MI DHD | Mt. Pleasant | 989 | 773-5921 | 773-4319 |
| Jackson | Jackson County | Jackson | 517 | 768-1662 | 788-4256 |
| Kalamazoo | Kalamazoo County | Kalamazoo | 269 | 373-5267 | 373-5060 |
| Kalkaska | District 10 | Kalkaska | 231 | 258-8669 | 258-2805 |
| Kent | Kent County | Grand Rapids | 616 | 632-7228 | 632-7085 |
| Keweenaw | Western UP Dist | Hancock | 906 | 482-7382 | 482-9410 |

STATE OF MICHIGAN CONTACTS

Communicable Disease and Emerging
Zoonotic Infectious Disease Divisions
Phone: 517-335-8165
Fax: 517-335-8263

Division of Immunizations
Phone: 517-335-8159
Fax: 517-335-9855

Bureau of Laboratories
Phone: 517-335-8063
Fax: 517-335-9631

After hours (**emergency calls only**): 517-335-9030

DIRECTORY OF MICHIGAN HEALTH DEPARTMENTS BY COUNTY PAGE 2

In general, health care providers should seek consultation regarding communicable disease prevention and control services through their local health departments.

Please check your local phone directory or health department website to see if there is a branch office in your community. Write that number here: _____

| COUNTY | HEALTH DEPT. | CO. OFFICE | AREA | PHONE | FAX |
|-------------------|-----------------------|---------------|------|--------------|--------------|
| Lake | District 10 | Baldwin | 231 | 745-4663 | 745-2501 |
| Lapeer | Lapeer County | Lapeer | 810 | 667-0448 | 667-0232 |
| Leelanau | Benzie-Leelanau DHD | Lake Leelanau | 231 | 256-0200 | 882-0143 |
| Lenawee | Lenawee County | Adrian | 517 | 264-5243 | 264-0790 |
| Livingston | Livingston County | Howell | 517 | 546-9850 | 545-9685 |
| Luce | LMAS DHD | Newberry | 906 | 293-5107 | 293-5724 |
| Mackinac | LMAS DHD | St. Ignace | 906 | 643-1100 | 643-0239 |
| Macomb | Macomb County | Mt. Clemens | 586 | 783-8190 | 493-0075 |
| Manistee | District 10 | Manistee | 231 | 723-3595 | 723-0150 |
| Marquette | Marquette County | Negaunee | 906 | 475-7844 | 475-4435 |
| Mason | District 10 | Ludington | 231 | 845-7381 | 845-9374 |
| Mecosta | District 10 | Big Rapids | 231 | 592-0130 | 592-9464 |
| Menominee | Delta-Men Dist | Menominee | 906 | 863-4451 | 863-7142 |
| Midland | Midland County | Midland | 989 | 832-6666 | 486-9064 |
| Missaukee | District 10 | Lake City | 231 | 839-7167 | 839-7908 |
| Monroe | Monroe County | Monroe | 734 | 240-7832 | 240-7838 |
| Montcalm | Mid-MI DHD | Stanton | 989 | 831-3615 | 831-3666 |
| Montmorency | District 4 | Atlanta | 989 | 785-4428 | 734-3866 |
| Muskegon | Muskegon County | Muskegon | 231 | 724-4421 | 724-1325 |
| Newaygo | District 10 | White Cloud | 231 | 689-7300 | 689-5295 |
| Oakland | Oakland County | Pontiac | 248 | 858-1286 | 858-0178 |
| Oceana | District 10 | Hart | 231 | 873-2193 | 873-4366 |
| Ogemaw | District 2 | West Branch | 989 | 345-5020 | 343-1896 |
| Ontonagon | Western UP Dist | Ontonagon | 906 | 884-4485 | 884-2358 |
| Osceola | Cent MI DHD | Reed City | 231 | 832-5532 | 832-1020 |
| Oscoda | District 2 | Mio | 989 | 826-3970 | 343-1896 |
| Otsego | Health Dept. of NW MI | Gaylord | 800 | 432-4121 | 231-547-6238 |
| Ottawa | Ottawa County | Holland | 616 | 396-5266 | 393-5767 |
| Presque Isle | District 4 | Rogers City | 989 | 734-4723 | 785-2217 |
| Roscommon | Cent MI DHD | Prudenville | 989 | 366-9166 | 366-8921 |
| Saginaw | Saginaw County | Saginaw | 989 | 758-3887 | 758-3888 |
| St. Clair | St. Clair County | Port Huron | 810 | 987-5300 | 985-4340 |
| St. Joseph | Branch/Hills/St Jo | Three Rivers | 269 | 273-2161x241 | 273-2452 |
| Sanilac | Sanilac County | Sandusky | 810 | 648-4098x162 | 648-5276 |
| Schoolcraft | LMAS DHD | Manistique | 906 | 341-6951 | 341-5230 |
| Shiawassee | Shiawassee County | Corunna | 989 | 743-2355 | 743-2362 |
| Tuscola | Tuscola County | Caro | 989 | 673-8114 | 673-7490 |
| Van Buren | Van Buren-Cass DHD | Lawrence | 269 | 621-3143 | 621-2725 |
| Washtenaw | Washtenaw County | Ypsilanti | 734 | 544-6700 | 544-6706 |
| Wayne (out-Wayne) | Wayne County | Wayne | 734 | 727-7078 | 313-967-3044 |
| Detroit | Detroit City | Detroit | 313 | 876-4000 | 877-9286 |
| Wexford | District 10 | Cadillac | 231 | 775-9942 | 775-4127 |

STATE OF MICHIGAN CONTACTS

Communicable Disease and Emerging
Zoonotic Infectious Disease Divisions
Phone: 517-335-8165
Fax: 517-335-8263

Division of Immunizations
Phone: 517-335-8159
Fax: 517-335-9855

Bureau of Laboratories
Phone: 517-335-8063
Fax: 517-335-9631

After hours (emergency calls only): 517-335-9030

NOTES

While every attempt has been made to accurately reflect the legal duties defined by the Michigan communicable disease rules, this booklet should not be considered a substitute for private legal counsel, or as an alternative to understanding and following the rules this booklet strives to summarize.

For more information, please consult the Michigan legislature website, which houses the Michigan Public Health Code, at:

www.michiganlegislature.org
and

www.legislature.mi.gov/documents/mcl/pdf/mcl-act-368-of-1978.pdf

or the Michigan Department of Licensing and Regulatory Affairs website, which houses the Michigan Administrative Code, at:

<https://www.michigan.gov/lara/bureau-list/moahr/admin-rules>

and

[http://www.legislature.mi.gov/\(S\(w45dnngsmrst4d2uvwhl2hpi0\)\)/mileg.aspx?page=GetObject&objectname=mcl-333-5131](http://www.legislature.mi.gov/(S(w45dnngsmrst4d2uvwhl2hpi0))/mileg.aspx?page=GetObject&objectname=mcl-333-5131)



MDHHS is an Equal Opportunity Employer, Services and Programs Provider